Neurocrine BiosciencesNBIX
NBIX
About: Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Employees: 1,800
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
44% more call options, than puts
Call options by funds: $92.7M | Put options by funds: $64.6M
2.07% more ownership
Funds ownership: 93.17% [Q4 2024] → 95.24% (+2.07%) [Q1 2025]
3% less funds holding
Funds holding: 590 [Q4 2024] → 572 (-18) [Q1 2025]
11% less first-time investments, than exits
New positions opened: 74 | Existing positions closed: 83
17% less funds holding in top 10
Funds holding in top 10: 12 [Q4 2024] → 10 (-2) [Q1 2025]
18% less capital invested
Capital invested by funds: $12.9B [Q4 2024] → $10.5B (-$2.37B) [Q1 2025]
29% less repeat investments, than reductions
Existing positions increased: 179 | Existing positions reduced: 251
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$115
16%
downside
Avg. target
$155
13%
upside
High target
$182
33%
upside
10 analyst ratings
9 positive
90%
1 neutral
10%
0 negative
0%
Morgan Stanley Jeffrey Hung | 10%upside $150 | Overweight Maintained | 22 Jul 2025 |
Truist Securities Danielle Brill | 19%upside $163 | Buy Initiated | 21 Jul 2025 |
Goldman Sachs Corinne Johnson | 33%upside $182 | Buy Initiated | 10 Jul 2025 |
UBS Ashwani Verma | 27%upside $174 | Buy Maintained | 9 Jul 2025 |
RBC Capital Brian Abrahams | 6%upside $145 | Outperform Reiterated | 2 Jun 2025 |
Financial journalist opinion
Based on 9 articles about NBIX published over the past 30 days
Positive
Zacks Investment Research
2 days ago
CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those looking for undervalued stocks?
Neutral
Zacks Investment Research
1 week ago
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
PRNewsWire
2 weeks ago
Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition
Technology-enabled research approach and AI-powered analysis identify unmet needs in patients with congenital adrenal hyperplasia SAN FRANCISCO , July 15, 2025 /PRNewswire/ -- PicnicHealth , a health technology company dedicated to advancing the next generation of non-interventional research, today announced its research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), the CAHtalog® Registry, identified an unmet need in patients with classic congenital adrenal hyperplasia (CAH). Using PicnicHealth's AI-powered technology to curate medical records and enable remote participation, the study revealed that CAH patients require lifelong, continuous adjustments to glucocorticoid dosing—the current standard treatment—to maintain condition control.
Neutral
PRNewsWire
2 weeks ago
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025
Approximately 95% of adult and pediatric patients were exposed to supraphysiologic doses of glucocorticoids and/or experienced elevated androstenedione levels at least once during their treatment journey Real-world findings underscore long-term challenges of managing classic congenital adrenal hyperplasia and highlight clinical need for therapies to reduce androgen excess without high glucocorticoid doses SAN DIEGO , July 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from a new analysis using real-world data from CAHtalog ® , a comprehensive registry of patients with classic congenital adrenal hyperplasia in the United States. The analysis demonstrated significant variability in glucocorticoid treatment regimens and frequent changes in health status and outcomes over time in both pediatric and adult patients.
Neutral
PRNewsWire
2 weeks ago
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductions Substantial improvements in insulin resistance were also observed in both adult and pediatric patients treated with CRENESSITY compared with placebo through one year of treatment SAN DIEGO , July 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies showing favorable trends in improvement of weight-related outcomes in patients with classic congenital adrenal hyperplasia who were treated with CRENESSITY® (crinecerfont) for up to one year. These data were presented at the Endocrine Society's Annual Meeting, ENDO 2025, that is taking place July 12-15 in San Francisco.
Neutral
PRNewsWire
2 weeks ago
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
One-year data from CAHtalyst™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasia Results build upon previously reported one-year data from CAHtalyst™ Pediatric study SAN DIEGO , July 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new one-year data from the CAHtalyst™ Adult study of CRENESSITY® (crinecerfont) showing that patients achieved lasting, more physiologic glucocorticoid doses, while adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained at or below baseline levels. These data complement the recently announced CAHtalyst™ Pediatric one-year results and were presented at the Endocrine Society's Annual Meeting, ENDO 2025, that is taking place July 12-15 in San Francisco.
Neutral
PRNewsWire
3 weeks ago
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
Conference Call and Webcast Scheduled for Wednesday, July 30 SAN DIEGO , July 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.
Positive
Seeking Alpha
3 weeks ago
Neurocrine Biosciences: Still A Buy After 30% Uplift Since My Last Coverage
Neurocrine's core assets, INGREZZA and Crenessity, can drive strong revenue growth with robust patent protection and significant market underpenetration. The pharma's pipeline is advancing, with multiple late-stage studies in major depressive disorder and schizophrenia offering substantial upside if successful. Competition remains a risk, but INGREZZA and Crenessity face limited near-term threats; pipeline assets could add billions in value if data is positive.
Neutral
PRNewsWire
4 weeks ago
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
SAN DIEGO , June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of investigational compound NBIP-01435 in healthy adult participants. NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist administered as a subcutaneous injection for the potential treatment of congenital adrenal hyperplasia (CAH).
Positive
MarketBeat
1 month ago
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
With the notable exceptions of Novo Nordisk A/S NYSE: NVO and Eli Lilly & Co. NYSE: LLY, biotechnology stocks had a rough time attracting investment capital in 2024. Small- and mid-cap biotech stocks struggled to raise capital in a higher-for-longer interest rate environment.
Charts implemented using Lightweight Charts™